Introduction {#S1}
============

COVID-19 has become one of the leading causes of death worldwide. It is estimated that 15--20% of cases require hospitalization and 3--5% require critical care. While experience with COVID-19 continues to grow, reported mortality rates range from 50--97% in those requiring mechanical ventilation.^[@R1]-[@R6]^ These are significantly higher than the published mortality rates ranging from 35--46% for patients intubated with H1N1 influenza pneumonia and other causes of acute respiratory distress syndrome (ARDS).^[@R7]-[@R10]^

These high mortality rates have raised concerns as to whether invasive mechanical ventilation should be avoided in the context of COVID-19.^[@R11]-[@R14]^ To help address the growing concern that critical illness, and specifically mechanical ventilation, are associated with a high risk of death, we conducted a retrospective cohort study of critically ill patients with COVID-19 across our academic health system.

Methods {#S2}
=======

This is an observational cohort study of all patients with COVID-19 admitted to six COVID-designated intensive care units (ICUs) at three Emory Healthcare acute-care hospitals in Atlanta, Georgia from March 6, 2020 through April 17, 2020. COVID-19 status was based upon a positive SARS-CoV-2 PCR assay, performed either by the Georgia Department of Public Health, a referral laboratory, or the hospital-based clinical laboratory. Patient data, including sociodemographic information, clinical data, and laboratory data, were obtained from the electronic medical record.

Data were abstracted through April 21, 2020. Data were analyzed using a chi-square or Wilcoxon rank sum test for categorical and continuous variables, respectively, with a 2-sided p-value \< 0.05 considered statistically significant (Stata Version 12.1). This study was approved by the Emory University Institutional Review Board.

Results {#S3}
=======

Patient Characteristics {#S4}
-----------------------

From March 6 through April 17, 2020, 217 critically ill adults with COVID-19 infection were admitted to the ICU ([Figure 1A](#F1){ref-type="fig"}). The median patient age was 64 (interquartile range \[IQR\] 54--73), with 49 (22.6%) patients who were 75 years or older ([Table 1](#T1){ref-type="table"}). There were 98 (45.2%) females and the majority of patients were black (153 \[70.5%\]). Hypertension was the most common comorbid condition (134 \[61.7%\]), followed by diabetes (99, \[45.6%\]). Twenty-one patients (9.7%) had morbid obesity, with a body mass index (BMI) of 40 or greater.

ICU admission and Interventions {#S5}
-------------------------------

Initial ICU clinical findings, critical care interventions, and outcomes are summarized in [Table 2](#T2){ref-type="table"}. On admission to the ICU, the median SOFA score was 7 (IQR 5--11), the median D-dimer was 1731 ng/ml (IQR 934--6948; upper limit of normal 298 ng/ml), and the median C-reactive protein was 190 mg/L (IQR 126--262; upper limit of normal 10 mg/L). The median initial PaO~2~/FiO~2~ ratio was 132 (IQR 100--178).

There were 165 (76.0%) patients who received invasive mechanical ventilation. The median static lung compliance on the first day of intubation was 34 ml/cmH~2~O (IQR 28--46). A total of 143 (65.9%) patients required vasopressor support for shock and 63 (29.0%) required renal replacement therapy, either in the form of continuous renal replacement therapy or intermittent hemodialysis. Use of inhaled pulmonary vasodilators was relatively uncommon (22 \[10.1%\]) and four (1.8%) patients received extracorporeal membrane oxygenation (ECMO). Overall, 114 (52.5%) patients received at least one dose of hydroxychloroquine and 49 (22.6%) patients were enrolled in the NIH-funded adaptive clinical treatment trial (ACTT) of remdesivir ([ClinicalTrials.gov](http://ClinicalTrials.gov) [NCT04280705](https://clinicaltrials.gov/ct2/show/NCT04280705)).

ICU Outcomes {#S6}
------------

Among the 217 patients in the cohort, 129 (59.4%) have been transferred alive from the ICU, 52 (23.9%) died in the ICU (four additional deaths occurred among patients transferred to the floor), and 36 (16.6%) remain in the ICU, of whom 14 (38.9%) are still mechanically ventilated ([Figure 1a](#F1){ref-type="fig"}). The median ICU length of stay for patients still in the ICU is 12 days (IQR 10--18). Among patients who received invasive mechanical ventilation, ICU mortality is 28.5% (47/165) and hospital mortality is 29.7% (49/165) ([Figure 1b](#F2){ref-type="fig"}).

The median age of patients who died was significantly older than for those who survived (70 years \[IQR 63--77\] vs. 61 years \[IQR 51 -- 69\]; p-value \< 0.001) ([Table 1](#T1){ref-type="table"}). Race and female sex did not differ according to survival, but patients who died were less likely to be morbidly obese and more likely to have coronary artery disease.

Patients who died had a higher Sequential Organ Failure Assessment (SOFA) score on ICU admission (median 9 \[IQR 6--13\]) than those who survived (median 7 \[IQR 4--10\]; p-value 0.002) ([Table 2](#T2){ref-type="table"}). Median D-dimer values were more than two times higher in those who died than those who survived (3780 \[IQR 1425 -- 19468\] vs. 1545 \[IQR 890--3514\]; p-value 0.002). Similarly, the initial C-reactive protein and PaO~2~/FiO~2~ ratios were significantly worse in patients who died in the ICU (p-values 0.003 and 0.001, respectively). Compared to those who survived, patients who died in the ICU were more likely to have respiratory failure requiring invasive mechanical ventilation (90.4% vs. 66.7%; p-value \< 0.001), shock requiring vasopressors (92.3% vs. 50.4%, p-value \<0.001), and renal failure requiring renal replacement therapy (53.9% vs 14.7%, p value \<0.001).

Overall, mortality among patients who received vasopressors was 33.6% (48/143), while 28 (44.5%) of 63 patients with renal failure requiring renal replacement therapy died. Half of the patients who received inhaled vasodilator for refractory hypoxemia died (11/22). Among the 52 patients who died in the ICU, including three patients who had an advance directive not to be intubated, the median time from ICU admission to death was 8 days (IQR 5--12).

Discussion {#S7}
==========

Our early experience with this large cohort of critically ill patients with COVID-19 demonstrates a mortality rate of 25.8% overall, which is substantially lower than the 50 -- 97% reported in the published literature to date.^[@R1]-[@R6]^ Additionally, the 29.7% mortality for the approximately three-quarters of patients in our cohort who required mechanical ventilation is also markedly lower than previous reports. These data indicate that a majority of critically ill patients with COVID-19 can have good clinical outcomes and support the ongoing use of mechanical ventilation for patients with acute respiratory failure.

In some of the earliest reports of COVID-19 from Wuhan, mortality rates among those admitted to ICUs ranged from 52--62%, and increased to 86--97% among those requiring invasive mechanical ventilation.^[@R5],[@R6],[@R15],[@R16]^ In more recent data from the United Kingdom, 67% of those who had received mechanical ventilation died, as compared to 22% of patients intubated with viral pneumonia in the preceding three years.^[@R3]^ Early reports of smaller cohorts from Seattle, where some of the first COVID-19 outbreaks occurred in the United States, indicated that 50--67% of patients admitted to the ICU and 71--75% of those receiving invasive mechanical ventilation died.^[@R1],[@R2]^ A recently published report from New York also found high mortality of 88.1% among those who required mechanical ventilation.^[@R4]^

Taken together, these reports have raised concerns that survival among those receiving mechanical ventilation is exceedingly poor.^[@R11]-[@R14],[@R17]^ In contrast to the majority of prior reports, our data provide evidence that mortality rates in COVID-19 can be comparable to those seen with ARDS and other infectious pneumonias.^[@R7]-[@R10]^

In our cohort, mortality was associated with older age, with 30.1% mortality in those age 65 and above as compared to 9.1% in those under age 55. Mortality was also associated with the presence of coronary artery disease, severity of illness on arrival to the ICU, and need for ICU interventions including mechanical ventilation, vasopressor support, renal replacement therapy and inhaled vasodilators. Approximately half of our cohort received at least one dose of hydroxychloroquine and nearly one-quarter received at least one dose of a study drug as part of the ACTT trial (remdesivir vs. placebo), but there was no difference in survival for either of those groups. Finally, although 36 (16.6%) patients are still admitted to the ICU at the time of this report, 87 (40.1%) have been discharged from the hospital.

Several local and regional considerations may have influenced the observed outcomes. First, the arrival and peak of the COVID-19 pandemic in Georgia were later than in many of the regions from earlier reports. This delay provided time to establish organizational structures, acquire equipment, prepare personnel, create consensus-driven clinical protocols, and align resources across a large healthcare system. In addition, while patient volumes did merit the re-designation of several specialty intensive care units as COVID ICUs, all critically ill patients with COVID-19 were admitted to pre-existing ICUs and cared for by critical care teams with experience managing acute respiratory failure and at standard patient-to-provider ratios. Further, while an analysis of the impact of clinical interventions on survival is beyond the scope of this brief report, our internal guidelines emphasized early intubation and standard lung-protective ventilation strategies. Future studies are needed to better understand the impact of individual patient risk factors, clinical interventions and treatments, and health system factors that can improve mortality in the face of this global pandemic.

Conclusion {#S8}
==========

In a cohort of critically ill adults with COVID-19, we report an early mortality rate of 25.8% overall and 29.7% for patients who received mechanical ventilation. While there may be a several factors underlying these findings, these results suggest that most patients with acute respiratory failure from COVID-19 may recover, even with severe disease requiring intubation and mechanical ventilation.

We would like to extend our most profound thanks and gratitude to our colleagues in the Emory Critical Care Center and Emory Healthcare who have worked so hard to provide excellent clinical care during this global pandemic.
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###### 

Sociodemographic and baseline clinical characteristics of patients admitted to a COVID-ICU.

  -------------------------------------------------------------------------------------------------------------------------------
  Characteristic\                       All\            Survived ICU\   Died in ICU\    p-value[\*](#TFN1){ref-type="table-fn"}
  (n\[%\] unless otherwise indicated)   (n=217)         (n=129)         (n=52)          
  ------------------------------------- --------------- --------------- --------------- -----------------------------------------
   Age, median (IQR)                    64 (54 -- 73)   61 (51 -- 69)   70 (63 -- 77)   **\< 0.001**

   Age \<55                             55 (25.3)       38 (29.5)       7 (13.5)        **0.024**

   Age 55-64                            56 (25.8)       40 (31.0)       9 (17.3)        0.061

   Age 65-74                            57 (26.3)       31 (24.0)       18 (34.6)       0.147

   Age ≥ 75                             49 (22.6)       20 (15.5)       18 (34.6)       **0.004**

   Female                               98 (45.2)       58 (45.0)       28 (53.9)       0.279

  Race                                                                                  

   White                                39 (18.0)       29 (22.5)       6 (11.5)        0.092

   Black                                153 (70.5)      90 (69.8)       38 (73.1)       0.658

   Asian                                7 (3.2)         1 (0.8)         2 (3.9)         0.143

   Other/unknown,                       18 (8.3)        9 (7.0)         6 (11.5)        0.314

  BMI, median (IQR)                     30 (26 -- 35)   31 (27 -- 36)   29 (26 -- 32)   0.0628

   BMI ≥ 40                             21 (9.7)        16 (12.4)       1 (1.9)         **0.029**

  HTN                                   134 (61.7)      83 (64.3)       34 (65.4)       0.894

  CHF                                   41 (18.9)       25 (19.4)       12 (23.1)       0.577

  CAD                                   31 (14.3)       15 (11.6)       13 (25.0)       **0.024**

  DM                                    99 (45.6)       60 (46.5)       26 (50.0)       0.671

  CKD/ESRD                              58 (26.7)       33 (25.6)       20 (38.5)       0.085

  Asthma                                19 (8.8)        13 (10.1)       3 (5.8)         0.356

  COPD                                  21 (9.7)        14 (10.9)       4 (7.7)         0.520
  -------------------------------------------------------------------------------------------------------------------------------

p-value: chi-square or Wilcoxon rank sum test comparing those who survived vs. died in the ICU.

BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; ESRD = end-stage renal disease; HTN = hypertension; IQR = interquartile range.

###### 

Patient characteristics on ICU admission, ICU clinical interventions, and outcomes.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic\                            All\                 Survived ICU\        Died in ICU\           p-value[\*](#TFN3){ref-type="table-fn"}
  (n\[%\] unless otherwise indicated)        (n=217)              (n=129)              (n=52)                 
  ------------------------------------------ -------------------- -------------------- ---------------------- -----------------------------------------
  **Initial ICU clinical characteristics**                                                                    

   SOFA, median (IQR)                        7 (5 -- 11)          7 (4 -- 10)          9 (6 -- 13)            **0.002**

   D-dimer, median (IQR)                     1731 (934 -- 6948)   1545 (890 -- 3514)   3780 (1425 -- 19468)   **0.002**

   C-reactive protein, median (IQR)          190 (126 -- 262)     167 (112 -- 241)     224 (164 -- 309)       **0.003**

   P/F ratio, median (IQR)                   132 (100 -- 178)     144 (107 -- 196)     114 (88 -- 148)        **0.001**

  **ICU Interventions**                                                                                       

   Any Mechanical Ventilation                165 (76.0)           86 (66.7)            47 (90.4)              **\< 0.001**

   Initial static compliance, median (IQR)   34 (28 -- 46)        33 (28 -- 41)        35 (27 -- 47)          0.778

   Ventilator days, median (IQR)             8 (4 -- 12)          7 (4 -- 11)          8 (4 -- 12)            0.989

   Any Vasopressors                          143 (65.9)           65 (50.4)            48 (92.3)              **\< 0.001**

   Vasopressor days, median (IQR)            5 (3 -- 9)           4 (2 -- 7)           6 (3 -- 9)             **0.021**

   Any CRRT/HD                               63 (29.0)            19 (14.7)            28 (53.9)              **\< 0.001**

   CRRT/HD days, median (IQR)                9 (4 -- 14)          11 (6 -- 17)         6 (3 -- 12)            **0.033**

   Inhaled vasodilator                       22 (10.1)            6 (4.7)              11 (21.1)              **\<0.001**

   Any ECMO                                  4 (1.8)              2 (1.5)              0                      0.367

   Hydroxychloroquine                        114 (52.5)           69 (53.5)            27 (51.9)              0.849

   ACTT (remdesivir or placebo)              49 (22.6)            29 (22.5)            11 (21.1)              0.846

  **Outcomes**                                                                                                

   ICU days, median (IQR)                    8 (4 -- 13)          7 (3 -- 12)          8 (5 -- 12)            0.382

   Hospital days, median (IQR)               13 (9 -- 20)         15 (9 -- 21)         11 (7 -- 14)           **0.0003**
  -----------------------------------------------------------------------------------------------------------------------------------------------------

p-value: chi-square or Wilcoxon rank sum test comparing those who survived vs. died in the ICU.

ACTT = adaptive clinical treatment trial; CRRT = continuous renal replacement therapy; ECMO = extracorporeal membrane oxygenation; HD = hemodialysis; IQR = interquartile range; LOS = length of stay; SOFA = Sequential Organ Failure Assessment.
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